Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Reducing morbidity and mortality in high risk patients with statins Singh V; Deedwania PVasc Health Risk Manag 2009[]; 5 (2): 495-507Residual coronary heart disease remains a significant problem even after adequate statin therapy for cardiovascular risk reduction as currently recommended by the Adult Treatment Panel III (ATP-III) of the National Cholesterol Education Program (NCEP). This is particularly true for the high risk patients as defined by ATP-III that includes those patients who have a greater than 20% 10-year risk of adverse cardiac events. For such patients the current goal of a low-density lipoprotein cholesterol (LDL-cholesterol) maintenance level of < or =100 mg/dL plasma appears to be suboptimal. Accumulating data from several recent randomized studies of more aggressive LDL-cholesterol reduction to levels below 70 mg/dL in the high risk patients favor acceptance of such a new lower target for LDL-cholesterol using more intensive statin therapy which would affect the treatment strategy for patients with coronary heart disease pre-percutaneous intervention, metabolic syndrome, diabetes mellitus, congestive heart failure, cerebrovascular disease and chronic kidney disease.|Atorvastatin[MESH]|Cardiovascular Diseases/complications/drug therapy[MESH]|Cholesterol, LDL/*drug effects[MESH]|Coronary Disease/complications/*drug therapy/*mortality[MESH]|Diabetes Complications/drug therapy[MESH]|Dose-Response Relationship, Drug[MESH]|Heptanoic Acids/administration & dosage/*therapeutic use[MESH]|Humans[MESH]|Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/*therapeutic use[MESH]|Intracranial Arteriosclerosis/complications/drug therapy[MESH]|Kidney Failure, Chronic/complications/drug therapy[MESH]|Metabolic Diseases/complications/drug therapy[MESH]|Practice Guidelines as Topic[MESH]|Pyrroles/administration & dosage/*therapeutic use[MESH]|Randomized Controlled Trials as Topic[MESH]|Risk Factors[MESH] |